Sandbox aparna: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 45: Line 45:
::::*Preferred regimen: [[Imipenem]]/[[Cilastatin]] 60–100 mg/kg/day IV for ≥ 8weeks {{and}}[[Ampicillin]] 300 mg/kg/day IV for ≥ 8weeks
::::*Preferred regimen: [[Imipenem]]/[[Cilastatin]] 60–100 mg/kg/day IV for ≥ 8weeks {{and}}[[Ampicillin]] 300 mg/kg/day IV for ≥ 8weeks
::::*Alternate regimen: [[Ceftriaxone]] 100 mg/kg/day IV/IM  {{and}}[[Ampicillin]] 300 mg/kg/day IV for ≥ 8weeks
::::*Alternate regimen: [[Ceftriaxone]] 100 mg/kg/day IV/IM  {{and}}[[Ampicillin]] 300 mg/kg/day IV for ≥ 8weeks
:*3. '''Meningitis'''<ref name="pmid15494903">{{cite journal| author=Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al.| title=Practice guidelines for the management of bacterial meningitis. | journal=Clin Infect Dis | year= 2004 | volume= 39 | issue= 9 | pages= 1267-84 | pmid=15494903 | doi=10.1086/425368 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15494903  }}</ref>   
 
::*3.1 '''Ampicillin susceptible'''
:*3. '''Meningitis'''<ref name="pmid15494903">{{cite journal| author=Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al.| title=Practice guidelines for the management of bacterial meningitis. | journal=Clin Infect Dis | year= 2004 | volume= 39 | issue= 9 | pages= 1267-84 | pmid=15494903 | doi=10.1086/425368 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15494903  }}</ref>  ::*3.1 '''Ampicillin susceptible'''
:::* Preferred regimen: [[Ampicillin]] 12 g/day IV q4h {{and}}[[Gentamicin]] 5 mg/kg/day IV q8h
:::* Preferred regimen: [[Ampicillin]] 12 g/day IV q4h {{and}}[[Gentamicin]] 5 mg/kg/day IV q8h
::*3.2 '''Ampicillin resistant'''
::*3.2 '''Ampicillin resistant'''
Line 52: Line 52:
::*3.3 '''Ampicillin and vancomycin resistant'''
::*3.3 '''Ampicillin and vancomycin resistant'''
:::* Preferred regimen: [[Linezolid]] 600 mg IV q12h
:::* Preferred regimen: [[Linezolid]] 600 mg IV q12h
:*4. '''Urinary tract infections''' <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:*4. '''Urinary tract infections''' <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
::* Preferred regimen (1): [[Nitrofurantoin]] 100 mg PO q6h for 5 days  
::* Preferred regimen (1): [[Nitrofurantoin]] 100 mg PO q6h for 5 days  
::* Preferred regimen (2): [[Fosfomycin]] 3 g PO single dose
::* Preferred regimen (2): [[Fosfomycin]] 3 g PO single dose
::* Preferred regimen (3): [[Amoxicillin]] 875 mg to 1 g PO q12h for 5 days
::* Preferred regimen (3): [[Amoxicillin]] 875 mg to 1 g PO q12h for 5 days
:*5. '''Intra abdominal or Wound infections''' <ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:*5. '''Intra abdominal or Wound infections''' <ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
Line 63: Line 62:
::* Alternative regimen(Penicillin allergy or high-level Penicillin resistance): [[Vancomycin]]
::* Alternative regimen(Penicillin allergy or high-level Penicillin resistance): [[Vancomycin]]
::* Alternative regimen(For complicated skin-skin structure and intra-abdominal infection): [[Tigecycline]] 100 mg IV single dose and 50 mg IV q12h
::* Alternative regimen(For complicated skin-skin structure and intra-abdominal infection): [[Tigecycline]] 100 mg IV single dose and 50 mg IV q12h


* [[Enterococcus faecium]]
* [[Enterococcus faecium]]
Line 80: Line 76:
:::* Preferred regimen (2): [[Daptomycin]] 6 mg/kg/day IV  
:::* Preferred regimen (2): [[Daptomycin]] 6 mg/kg/day IV  
:*2. '''Endocarditis'''
:*2. '''Endocarditis'''
::*2.1 '''Endocarditis in Adults''' <ref name="Baddour-2005">{{Cite journal  | last1 = Baddour | first1 = LM. | last2 = Wilson | first2 = WR. | last3 = Bayer | first3 = AS. | last4 = Fowler | first4 = VG. | last5 = Bolger | first5 = AF. | last6 = Levison | first6 = ME. | last7 = Ferrieri | first7 = P. | last8 = Gerber | first8 = MA. | last9 = Tani | first9 = LY. | title = Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = e394-434 | month = Jun | year = 2005 | doi = 10.1161/CIRCULATIONAHA.105.165564 | PMID = 15956145 }}</ref>
::*2.1 '''Endocarditis in Adults'''  
:::* '''Strains Susceptible to Penicillin, Gentamicin, and Vancomycin'''
:::*2.1.1 '''Strains Susceptible to Penicillin, Gentamicin, and Vancomycin'''
::::* Preferred regimen: ([[Ampicillin|Ampicillin]] 12 g/day IV for 4–6weeks {{or}}[[Penicillin G|Aqueous crystalline penicillin G sodium]] 18–30 MU/day IV for 4–6weeks) {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM for 4–6 weeks
::::*Preferred regimen: ([[Ampicillin|Ampicillin]] 12 g/day IV for 4–6weeks {{or}}[[Penicillin G|Aqueous crystalline penicillin G sodium]] 18–30 MU/day IV for 4–6weeks) {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM for 4–6 weeks
::::*'''Note : In case of native valve endocarditis, 4-wk therapy recommended for patients with symptoms of illness ≤3 months and 6-wk therapy recommended for patients with symptoms >3 months and prosthetic valve or other prosthetic cardiac material a minimum of 6 wk of therapy recommended '''
::::*'''Note : In case of native valve endocarditis, 4-week therapy recommended for patients with symptoms of illness ≤3 months and 6-week therapy recommended for patients with symptoms >3 months and prosthetic valve or other prosthetic cardiac material a minimum of 6 week of therapy recommended '''
::::*Alternate regimen: [[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg/day IV for 6 weeks {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM for 6weeks  
::::* Alternate regimen: [[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg/day IV for 6 weeks {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM for 6weeks  
:::*Strains Susceptible to [[Penicillin]], [[Streptomycin]], and [[Vancomycin]] and Resistant to [[Gentamicin]]
:::*2.1.2 '''Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin'''
::::*Preferred regimen : ([[Ampicillin]] 12 g/day IV for 4–6 weeks {{or}}[[Penicillin G|Aqueous crystalline penicillin G sodium]] 24 MU/day IV for 4–6weeks){{and}}[[Streptomycin|Streptomycin sulfate]] 15 mg/kg/day IV/IM for 4–6weeks  
::::* Preferred regimen: ([[Ampicillin]] 12 g/day IV for 4–6 weeks {{or}}[[Penicillin G|Aqueous crystalline penicillin G sodium]] 24 MU/day IV for 4–6weeks){{and}}[[Streptomycin|Streptomycin sulfate]] 15 mg/kg/day IV/IM for 4–6weeks  
::::*Alternate regimen: [[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg/day IV 6weeks {{and}}[[Streptomycin|Streptomycin sulfate]] 15 mg/kg per 24 h IV/IM for 6weeks  
::::* Alternate regimen: [[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg/day IV 6weeks {{and}}[[Streptomycin|Streptomycin sulfate]] 15 mg/kg per 24 h IV/IM for 6weeks  
:::*Strains Resistant to [[Penicillin]] and Susceptible to [[Aminoglycoside]] and [[Vancomycin]]
:::*2.1.3 '''Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin'''
::::*β Lactamase–producing strain  
::::*2.1.3.1 '''β Lactamase–producing strain'''
::::*Preferred regimen : [[Ampicillin-sulbactam]] 12 g/day IV for 6weeks {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM 6weeks  
:::::* Preferred regimen: [[Ampicillin-sulbactam]] 12 g/day IV for 6weeks {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM 6weeks  
::::*Alternate regimen : [[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg/day IV for 6weeks {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM for 6weeks
:::::* Alternate regimen: [[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg/day IV for 6weeks {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM for 6weeks
::::*Intrinsic [[penicillin]] resistance : [[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg/day IV for 6weeks {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM for 6weeks
::::*2.1.3.2 '''Intrinsic penicillin resistance'''
:::*Strains Resistant to [[Penicillin]], [[Aminoglycoside]], and [[Vancomycin]]
:::::* Preferred regimen: [[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg/day IV for 6weeks {{and}}[[Gentamicin|Gentamicin sulfate]] 3 mg/kg/day IV/IM for 6weeks
::::*Preferred regimen : [[Linezolid]] 1200 mg/day IV/PO ≥8weeks {{or}}[[Quinupristin]]-[[Dalfopristin]]22.5 mg/kg/day IV ≥8weeks
:::*2.1.4 '''Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin''' 
::*2.2.Endocarditis in Pediatrics
::::*Preferred regimen(1): [[Linezolid]] 1200 mg/day IV/PO ≥8weeks  
:::*Strains Susceptible to [[Penicillin]], [[Gentamicin]], and [[Vancomycin]]
 
::::*Preferred regimen : ([[Ampicillin]] 300 mg/kg/day IV for 4–6 weeks {{or}}[[Penicillin]] 300,000U/kg/day IV for 4–6 weeks) {{and}}[[Gentamicin]] 3 mg/kg per 24 h IV/IM 4–6 weeks
::::*Preferred regimen(2): [[Quinupristin]]-[[Dalfopristin]]22.5 mg/kg/day IV ≥8weeks
::*2.2 '''Endocarditis in Pediatrics'''
:::*2.2.1 '''Strains Susceptible to Penicillin, Gentamicin, and Vancomycin'''
::::* Preferred regimen: ([[Ampicillin]] 300 mg/kg/day IV for 4–6weeks {{or}}[[Penicillin]] 300,000 U/kg/day IV for 4–6 weeks) {{and}}[[Gentamicin]] 3 mg/kg q24h IV/IM 4–6weeks
::::*'''Note : In case of native valve endocarditis, 4-wk therapy recommended for patients with symptoms of illness ≤3 months and 6-wk therapy recommended for patients with symptoms >3 months and prosthetic valve or other prosthetic cardiac material a minimum of 6 wk of therapy recommended '''
::::*'''Note : In case of native valve endocarditis, 4-wk therapy recommended for patients with symptoms of illness ≤3 months and 6-wk therapy recommended for patients with symptoms >3 months and prosthetic valve or other prosthetic cardiac material a minimum of 6 wk of therapy recommended '''
::::*Alternate regimen : [[Vancomycin]] 40 mg/kg/day IV for 6weeks {{and}}[[Gentamicin]] 3 mg/kg/day IV/IM for 6weeks
::::* Alternate regimen : [[Vancomycin]] 40 mg/kg/day IV for 6weeks {{and}}[[Gentamicin]] 3 mg/kg/day IV/IM for 6weeks
:::*Strains Susceptible to [[Penicillin]], [[Streptomycin]], and [[Vancomycin]] and Resistant to [[Gentamicin]]
:::*2.2.2 '''Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin'''
::::*Preferred regimen : ([[Ampicillin]] 300 mg/kg/day IV for 4–6 weeks {{or}}[[Penicillin]] 300,000 U/kg/day IV for 4–6 weeks) {{and}}[[Streptomycin]] 20–30 mg/kg/day IV/IM for 4–6 weeks
::::* Preferred regimen: ([[Ampicillin]] 300 mg/kg/day IV for 4–6weeks {{or}}[[Penicillin]] 300,000 U/kg/day IV for 4–6weeks) {{and}}[[Streptomycin]] 20–30 mg/kg/day IV/IM for 4–6 weeks
::::*Alternate regimen: [[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg/day IV for 6weeks {{and}}[[Streptomycin|Streptomycin sulfate]] 15 mg/kg/day IV/IM for 6weeks  
::::* Alternate regimen: [[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg/day IV for 6weeks {{and}}[[Streptomycin|Streptomycin sulfate]] 15 mg/kg/day IV/IM for 6weeks  
:::*Strains Resistant to [[Penicillin]] and Susceptible to [[Aminoglycoside]] and [[Vancomycin]]
:::*2.2.3 '''Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin'''
::::*β Lactamase–producing strain   
::::*2.2.3.1 '''β Lactamase–producing strain'''  
::::*Preferred regimen : [[Ampicillin-sulbactam]] 300 mg/kg/day IV for 6weeks {{and}}[[Gentamicin]] 3 mg/kg/day IV/IM for 6weeks
:::::* Preferred regimen: [[Ampicillin-sulbactam]] 300 mg/kg/day IV for 6weeks {{and}}[[Gentamicin]] 3 mg/kg/day IV/IM for 6weeks
::::*Alternate regimen : [[Vancomycin]] 40 mg/kg/day IV for 6weeks {{and}}[[Gentamicin]] 3 mg/kg/day IV/IM for 6weeks
:::::* Alternate regimen: [[Vancomycin]] 40 mg/kg/day IV for 6weeks {{and}}[[Gentamicin]] 3 mg/kg/day IV/IM for 6weeks
::::*Intrinsic penicillin resistance : [[Vancomycin]] 40 mg/kg/day IV {{and}}[[Gentamicin]] 3 mg/kg/day IV/IM for 6weeks
::::*2.2.3.2 '''Intrinsic penicillin resistance'''
:::*Strains Resistant to [[Penicillin]], [[Aminoglycoside]], and [[Vancomycin]]
[[Vancomycin]] 40 mg/kg/day IV {{and}}[[Gentamicin]] 3 mg/kg/day IV/IM for 6weeks
::::*Preferred regimen : [[Linezolid]] 30 mg/kg/day IV/PO ≥ 8weeks {{or}}[[Quinupristin]]-[[Dalfopristin]]22.5 mg/kg/day IV ≥ 8weeks
:::*2.2.4 '''Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin'''
::::*Preferred regimen(1): [[Linezolid]] 30 mg/kg/day IV/PO ≥ 8weeks  


:*'''3.Meningitis'''<ref name="pmid15494903">{{vcite2 journal |vauthors=Tunkel AR, Hartman BJ, Kaplan SL, et al. |title=Practice guidelines for the management of bacterial meningitis |journal=Clin. Infect. Dis. |volume=39 |issue=9 |pages=1267–84 |year=2004 |pmid=15494903 |doi=10.1086/425368 |url= |issn=}}</ref> 
::::*Preferred regimen(2): [[Quinupristin]]-[[Dalfopristin]]22.5 mg/kg/day IV ≥ 8weeks
::*[[Ampicillin]] susceptible
:::*Preferred regimen: [[Ampicillin]] 12 g/day IV q4h {{and}}[[Gentamicin]] 5 mg/kg/day IV q8h
::*[[Ampicillin]] resistant
:::*Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{and}}[[Gentamicin]] 5 mg/kg/day IV q8h
::*[[Ampicillin]] and [[vancomycin]] resistant
:::*Preferred regimen: [[Linezolid]] 600 mg IV q12h


:*'''4.Urinary tract infections''' <ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:*3. '''Meningitis'''<ref name="pmid15494903">{{cite journal| author=Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al.| title=Practice guidelines for the management of bacterial meningitis. | journal=Clin Infect Dis | year= 2004 | volume= 39 | issue= 9 | pages= 1267-84 | pmid=15494903 | doi=10.1086/425368 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15494903  }}</ref>
::*Preferred regimen : [[Nitrofurantoin]] 100 mg PO q6h for 5 days {{or}}[[Fosfomycin]] 3 g PO single dose {{or}}[[Amoxicillin]] 875 mg-1 g PO q12h for 5 days
::*3.1 '''Ampicillin susceptible'''
:::* Preferred regimen: [[Ampicillin]] 12 g/day IV q4h {{and}}[[Gentamicin]] 5 mg/kg/day IV q8h
::*3.2 '''Ampicillin resistant'''
:::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{and}}[[Gentamicin]] 5 mg/kg/day IV q8h
::*3.3 '''Ampicillin and vancomycin resistant'''
:::* Preferred regimen: [[Linezolid]] 600 mg IV q12h


:*4. '''Urinary tract infections'''
<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>::* Preferred regimen  (1):  [[Nitrofurantoin]] 100  mg PO q6h for 5 days
::* Preferred regimen (2): [[Fosfomycin]] 3 g PO single dose
::* Preferred regimen (3): [[Amoxicillin]] 875 mg to 1 g PO q12h for 5 days


:*5. '''Intra abdominal or Wound infections''' <ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:*5. '''Intra abdominal or Wound infections''' <ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>::* Preferred regimen(1): [[Penicillin]]  
::* Preferred regimen(1): [[Penicillin]]  
::* Preferred regimen(2): [[Ampicillin]]
::* Preferred regimen(2): [[Ampicillin]]
::* Alternative regimen(Penicillin allergy or high-level Penicillin resistance): [[Vancomycin]]
::* Alternative regimen(Penicillin allergy or high-level Penicillin resistance): [[Vancomycin]]
::* Alternative regimen(For complicated skin-skin structure and intra-abdominal infection): [[Tigecycline]] 100 mg IV single dose and 50 mg IV q12h
::* Alternative regimen(For complicated skin-skin structure and intra-abdominal infection): [[Tigecycline]] 100 mg IV single dose and 50 mg IV q12h

Revision as of 15:45, 15 July 2015

  • 1. Bacteremia[1]
  • 1.1 Ampicillin or Penicillin susceptible
  • 1.2 Ampicillin resistant and vancomycin susceptible or Penicillin allergy
  • 1.3 Ampicillin and Vancomycin resistant
  • 2.1 Endocarditis in Adults
  • 2.1.1 Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
  • Preferred regimen: (Ampicillin 12 g/day IV for 4–6weeks ORAqueous crystalline penicillin G sodium 18–30 MU/day IV for 4–6weeks) ANDGentamicin sulfate 3 mg/kg/day IV/IM for 4–6 weeks
  • Note : In case of native valve endocarditis, 4-wk therapy recommended for patients with symptoms of illness ≤3 months and 6-wk therapy recommended for patients with symptoms >3 months and prosthetic valve or other prosthetic cardiac material a minimum of 6 wk of therapy recommended
  • Alternate regimen: Vancomycin hydrochloride 30 mg/kg/day IV for 6 weeks ANDGentamicin sulfate 3 mg/kg/day IV/IM for 6weeks
  • 2.1.2 Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
  • 2.1.3 Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin
  • 2.1.3.1 β Lactamase–producing strain
  • 2.1.3.2 Intrinsic penicillin resistance
  • 2.1.4 Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin
  • 2.2 Endocarditis in Pediatrics
  • 2.2.1 Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
  • Preferred regimen: (Ampicillin 300 mg/kg/day IV for 4–6weeks ORPenicillin 300,000 U/kg/day IV for 4–6 weeks) ANDGentamicin 3 mg/kg q24h IV/IM 4–6weeks
  • Note : In case of native valve endocarditis, 4-wk therapy recommended for patients with symptoms of illness ≤3 months and 6-wk therapy recommended for patients with symptoms >3 months and prosthetic valve or other prosthetic cardiac material a minimum of 6 wk of therapy recommended
  • Alternate regimen : Vancomycin 40 mg/kg/day IV for 6weeks ANDGentamicin 3 mg/kg/day IV/IM for 6weeks
  • 2.2.2 Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
  • 2.2.3 Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin
  • 2.2.3.1 β Lactamase–producing strain
  • 2.2.3.2 Intrinsic penicillin resistance
  • 2.2.4 Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin
  • 3. Meningitis[4]  ::*3.1 Ampicillin susceptible
  • 3.2 Ampicillin resistant
  • 3.3 Ampicillin and vancomycin resistant
  • 4. Urinary tract infections [5]
  • Preferred regimen (1): Nitrofurantoin 100 mg PO q6h for 5 days
  • Preferred regimen (2): Fosfomycin 3 g PO single dose
  • Preferred regimen (3): Amoxicillin 875 mg to 1 g PO q12h for 5 days
  • 5. Intra abdominal or Wound infections [6]
  • Preferred regimen(1): Penicillin
  • Preferred regimen(2): Ampicillin
  • Alternative regimen(Penicillin allergy or high-level Penicillin resistance): Vancomycin
  • Alternative regimen(For complicated skin-skin structure and intra-abdominal infection): Tigecycline 100 mg IV single dose and 50 mg IV q12h
  • 1. Bacteremia[7]
  • 1.1 Ampicillin or Penicillin susceptible
  • 1.2 Ampicillin resistant and vancomycin susceptible or Penicillin allergy
  • 1.3 Ampicillin and Vancomycin resistant
  • 2. Endocarditis
  • 2.1 Endocarditis in Adults
  • 2.1.1 Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
  • Preferred regimen: (Ampicillin 12 g/day IV for 4–6weeks ORAqueous crystalline penicillin G sodium 18–30 MU/day IV for 4–6weeks) ANDGentamicin sulfate 3 mg/kg/day IV/IM for 4–6 weeks
  • Note : In case of native valve endocarditis, 4-week therapy recommended for patients with symptoms of illness ≤3 months and 6-week therapy recommended for patients with symptoms >3 months and prosthetic valve or other prosthetic cardiac material a minimum of 6 week of therapy recommended
  • Alternate regimen: Vancomycin hydrochloride 30 mg/kg/day IV for 6 weeks ANDGentamicin sulfate 3 mg/kg/day IV/IM for 6weeks
  • 2.1.2 Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
  • 2.1.3 Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin
  • 2.1.3.1 β Lactamase–producing strain
  • 2.1.3.2 Intrinsic penicillin resistance
  • 2.1.4 Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin
  • Preferred regimen(1): Linezolid 1200 mg/day IV/PO ≥8weeks
  • 2.2 Endocarditis in Pediatrics
  • 2.2.1 Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
  • Preferred regimen: (Ampicillin 300 mg/kg/day IV for 4–6weeks ORPenicillin 300,000 U/kg/day IV for 4–6 weeks) ANDGentamicin 3 mg/kg q24h IV/IM 4–6weeks
  • Note : In case of native valve endocarditis, 4-wk therapy recommended for patients with symptoms of illness ≤3 months and 6-wk therapy recommended for patients with symptoms >3 months and prosthetic valve or other prosthetic cardiac material a minimum of 6 wk of therapy recommended
  • Alternate regimen : Vancomycin 40 mg/kg/day IV for 6weeks ANDGentamicin 3 mg/kg/day IV/IM for 6weeks
  • 2.2.2 Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
  • 2.2.3 Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin
  • 2.2.3.1 β Lactamase–producing strain
  • 2.2.3.2 Intrinsic penicillin resistance

Vancomycin 40 mg/kg/day IV ANDGentamicin 3 mg/kg/day IV/IM for 6weeks

  • 2.2.4 Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin
  • Preferred regimen(1): Linezolid 30 mg/kg/day IV/PO ≥ 8weeks
  • 3. Meningitis[4]
  • 3.1 Ampicillin susceptible
  • 3.2 Ampicillin resistant
  • 3.3 Ampicillin and vancomycin resistant
  • 4. Urinary tract infections

[8]::* Preferred regimen (1): Nitrofurantoin 100  mg PO q6h for 5 days

  • Preferred regimen (2): Fosfomycin 3 g PO single dose
  • Preferred regimen (3): Amoxicillin 875 mg to 1 g PO q12h for 5 days
  • 5. Intra abdominal or Wound infections [9]::* Preferred regimen(1): Penicillin
  • Preferred regimen(2): Ampicillin
  • Alternative regimen(Penicillin allergy or high-level Penicillin resistance): Vancomycin
  • Alternative regimen(For complicated skin-skin structure and intra-abdominal infection): Tigecycline 100 mg IV single dose and 50 mg IV q12h
  1. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
  2. Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter |month= ignored (help)
  3. "Infective Endocarditis Diagnosis, Antimicrobial Therapy, and Management of Complications A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association".
  4. 4.0 4.1 Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM; et al. (2004). "Practice guidelines for the management of bacterial meningitis". Clin Infect Dis. 39 (9): 1267–84. doi:10.1086/425368. PMID 15494903.
  5. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  6. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
  7. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
  8. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  9. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.